




RealRate

PHARMACEUTICAL 2018

Neos Therapeutics Inc.
Rank 219 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2018

Neos Therapeutics Inc. Rank 219 of 349

The relative strengths and weaknesses of Neos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neos Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Neos Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is -252%, being 26% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	82,640
Cost of Goods Sold	12,391
Intangible Assets	16,348
Liabilities, Current	37,602
Liabilities, Non-Current	61,861
Other Assets	162
Other Compr. Net Income	-5.0
Other Expenses	46,881
Other Liabilities	0
Other Net Income	-9,231
Property and Equipment	8,203
Research and Development	8,957
Revenues	25,018
Selling, General and Administrative Expense	13,805

Output Variable	Value in 1000 USD
Assets	107,353
Liabilities	99,463
Expenses	82,034
Stockholders Equity	7,890
Net Income	-66,247
Comprehensive Net Income	-66,250
Economic Capital Ratio	-252%

